CYP Cocktail + ZIPALERTINIB for lung diseases

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 31 Jul 2023: Trial started, NCT05967689
  2. 1 Aug 2023: Trial registered, NCT05967689

The trials

NCT05967689: A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

State
Under way
Phase
Phase 2
People
220 planned
Started
31 Jul 2023
Primary completion
31 Aug 2028
Arms
DDI Substudy: CYP Cocktail Group
Results
None posted
  1. 31 Jul 2023: Trial started
  2. 1 Aug 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.